Novel therapeutic agents targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with colorectal carcinoma. However, these therapies are effective only in a subset of patients. Activating mutations in the KRAS gene are found in 30-40% of colorectal tumors and are associated with poor response to anti-EGFR therapies. Thus, KRAS mutation status can predict which patient may or may not benefit from anti-EGFR therapy. Although many diagnostic tools have been developed for KRAS mutation analysis, validated methods and standardized testing procedures are lacking. This poses a challenge for the optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Here we review the molecular basis of EGFR-targeted therapies and the resistance to treatment conferred by KRAS mutations. We also present guideline recommendations and a proposal for a European quality assurance program to help ensure accuracy and proficiency in KRAS mutation testing across the European Union.
|Autori:||VAN KRIEKEN JH; JUNG A; KIRCHNER T; CARNEIRO F; SERUCA R; BOSMAN FT; QUIRKE P; FLÉJOU JF; PLATO HANSEN T; DE HERTOGH G; JARES P; LANGNER C; HOEFLER G; LIGTENBERG M; TINIAKOS D; TEJPAR S; BEVILACQUA G; ENSARI A|
|Titolo:||KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program|
|Anno del prodotto:||2008|
|Appare nelle tipologie:||1.1 Articolo in rivista|